Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- MHLW to Temporarily Withdraw Recommendation of Preventive Cervical Cancer Vaccinations
June 18, 2013
- PMDA Building “Database on Unapproved Drugs” to Accelerate Elimination of Drug Lag
June 18, 2013
- Cabinet Approves PM Abe’s Growth Strategy, Regulatory Reform Plan
June 17, 2013
- Council to Discuss Problem of Prolonged Delivery Price Negotiations at Meeting on June 27
June 17, 2013
- Pharmaceutical Affairs Council Approves Revised Draft Plan to Reduce Manufacturing Costs of Blood Products
June 17, 2013
- CSIMC’s Expert Subcommittee on NHI Drug Pricing Affairs to Hold Hearings for Drug Pricing Organization at Next Meeting in July
June 14, 2013
- CSIMC Approves Plans for FY2013 Market Price Survey of Similar Size as 2 Years Ago
June 14, 2013
- CSIMC Expert Subcommittee: Reps Agree on Need to Redress Price Variations of Generics
June 13, 2013
- Japan’s Target Drug Market Size Revised Up to 12.8 Trillion Yen in 2020: Growth Strategy
June 13, 2013
- Reprocessing of Expired Anti-Influenza Drugs to Be Considered “If Necessary”
June 13, 2013
- Only About 50% of Doctors Aware of ADR Relief System: PMDA
June 12, 2013
- Half of Patients Unaware of New Anticoagulants: Healthy Japan 21 Promotion Forum Survey
June 11, 2013
- Expert Subcommittee to Begin Discussions on Next Year’s NHI Price Revision on June 12
June 11, 2013
- Director Kamada of HPB’s Economic Affairs Division Calls for Cooperation in Promoting Distribution Reform
June 11, 2013
- Bill to Amend PAL Unlikely to Be Enacted in Current Diet Session
June 10, 2013
- MHLW to Establish “PMDA-WEST” in Kansai Region in October
June 10, 2013
- Council Announces “Comprehensive STI Strategy” to Create One Trillion Yen Market for Regenerative Medicine by 2030
June 10, 2013
- Japan Set to Perk Up R&D to Expand Drug Market to 9 Trillion Yen in 2020
June 7, 2013
- MHLW Asks Industry Organization to Take Steps to Ensure Proper COI Management in Response to Diovan Scandal: HPB Director-General at Diet
June 7, 2013
- Abe Vows to Lift Ban on Online OTC Drug Sales; MHLW to Form Panel to Verify Safety
June 6, 2013
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…